News Release Details

Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023

June 27, 2023

RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors

RDT platform is focused on improving both tumor-targeting efficiency and safety over historic protein-based radioligand approaches

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, has announced it will present on its Radio DARPin Therapy (RDT) Platform at the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting being held from June 24-27 in Chicago, Illinois.

The presentation details are as follows:

Title: DARPin platform for the development of powerful targeting agents for radioligand therapy
Session Title: Innovative Radiopharmaceutical Development for Targeted Cancer Therapy
Session Number: SS39
Session Location & Timing: Room S504ab; June 27, 2023; 9:30–10:45 am local time
Order in Session: 6
Presentation Time: 10:15–10:35 am local time

Access to the slides presented at SNMMI will be available on the company website, under the "Scientific Documents” tab.

Molecular Partners’ RDT platform represents a unique and innovative approach for the delivery of radioactive payloads to solid tumors. Thanks to their small size and their high specificity and affinity, DARPins represent ideal vectors for efficient delivery of therapeutic radionuclides: RDT has the potential to selectively deliver radionuclides deeply into the targeted tumor, with long tumor retention, causing direct tumor cell killing, while limiting systemic side effects.

Molecular Partners is developing a portfolio of RDTs, both proprietary as well as in collaboration with external partners. The tumor-associated protein Delta-like ligand 3 (DLL3) is the first disclosed target of Molecular Partner’s proprietary RDT candidates.

Preclinical data shows that RDT can deliver high amount of radioactivity to tumors without accumulating in healthy tissues. Molecular Partners has also demonstrated that through DARPin engineering it can reduce the uptake of DARPin radio conjugates in the kidneys and therefore reduce kidney damage, a key limitation of protein-based radio therapies.

Authors & Affiliations:
Christian Lizak,1 Andreas Bosshart,1 Stephan Wullschleger,1 Martin Behe,2 Alain Blanc,2
Stefan Imobersteg,2 Alexandra Neculcea,1 Jacqueline Blunschi,1 Liridon Abduli,1 Sarah Schütz,1
Julia Wolter, 1 Christian Reichen,1 Amelie Croset,1 Alessandra Villa,1 Anne Goubier,1 Philippe Legenne,1 Roger Schibli,2 and Daniel Steiner1
1Molecular Partners AG, Schlieren-Zurich, Switzerland; 2Paul Scherrer Institute, Villingen, Switzerland

About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin (designed ankyrin repeat protein) therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and virology and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.; Find us on Twitter - @MolecularPrtnrs

Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates, expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials, the potential therapeutic and clinical benefits of Molecular Partners’ product candidates, the selection and development of future antiviral or other programs, and Molecular Partners’ expected expenses and cash utilization for 2023 and its expectation that its current cash resources will be sufficient to fund its operations and capital expenditure requirements into 2026. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, “would” and similar expressions, and are based on Molecular Partners AG’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners’ reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners’ ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners’ ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners’ product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners’ product candidates; clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners’ plans and development of any new indications for its product candidates; Molecular Partners’ commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners’ intellectual property position; Molecular Partners’ ability to identify and in-license additional product candidates; and other risks and uncertainties that are described in the Risk Factors section of Molecular Partners’ Annual Report on Form 20-F for the fiscal year ended December 31, 2022 filed with Securities and Exchange Commission (SEC) on March 9, 2023 and other filings Molecular Partners makes with the SEC. These documents are available on the Investors page of Molecular Partners’ website at Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further details, please contact:
Seth Lewis, Investor Relations
Tel: +1 781 420 2361

Antonio Ligi, Communications
Zürich-Schlieren, Switzerland
Tel: +41 79 723 36 81